ENvue Medical, Inc.: enters secured promissory note and amends Series X terms

What happened ENvue Medical, Inc. filed an 8-K reporting that on Oct 8, 2026 it entered into a Secured Promissory Note and Security Agreement with Alpha Capital Anstalt and that the lender funded an initial tranche of $250,000. The company also filed that on Oct 8, 2026 it entered into an Amendment Agreement with holders of at least 70% of the outstanding shares of its Series X non-voting convertible preferred stock to amend the Certificate of Designations, including lowering the conversion price to $0.50 per share. On Oct 12, 2026 the company filed the Certificate of Amendment with the Secretary of State of the State of Delaware.

Key details

• Loan facility: up to $1,000,000, initial tranche funded $250,000 on Oct 8, 2026.
• Interest: 10% per annum; upon an Event of Default interest increases to the lesser of 18% per annum or the highest rate permitted by law.
• Maturity and extensions: outstanding principal and accrued interest due Dec 31, 2026, with lender right to extend the maturity date in 3-month increments through Dec 31, 2028.
• Security: continuing security interest in substantially all of the company’s assets, including accounts, inventory, certain deposits, intellectual property and equity ownership of subsidiaries.
• Series X amendment: conversion price amended to $0.50 per share (subject to adjustment) and provisions governing subsequent equity sales and dilution were changed; amendment agreed by holders of at least 70% of the Series X shares and filed Oct 12, 2026.

Why it may matter

• Item 1.01: entry into a material definitive agreement (the Secured Promissory Note and Security Agreement and the Amendment Agreement).
• Item 2.03: creation of a direct financial obligation (the loan facility and outstanding tranche).
• Item 5.03: amendments to articles of incorporation or bylaws (Certificate of Amendment filed with Delaware).

This filing does not show why the insider traded or why the company acted.